慢性心力衰竭患者中β肾上腺素受体抑制相关的死亡率降低在糖尿病患者中更明显
该前瞻性队列研究纳入1797例慢性心力衰竭且左心室射血分数降低的患者,随访平均4年,用Cox回归分析糖尿病与药物剂量对全因死亡率的交互作用。结果显示,β受体阻滞剂剂量增加与死亡率降低相关,且糖尿病患者获益更大(交互作用P=0.027);ACEI剂量增加与死亡率降低相关,但两组效应相似(交互作用P=0.76)。
要点
- 糖尿病患者比非糖尿病患者接受更大剂量的β受体阻滞剂和ACEI。
- β受体阻滞剂剂量每增加1 mg/日,糖尿病患者死亡率降低8.9%(95%CI 5-12.6),非糖尿病患者降低3.5%(95%CI 0.7-6.3),交互作用P=0.027。
- ACEI剂量每增加1 mg/日,糖尿病患者死亡率降低5.9%(95%CI 2.5-9.2),非糖尿病患者降低5.1%(95%CI 2.6-7.6),交互作用P=0.76。
核心结论
- 在慢性心力衰竭且左心室射血分数降低的患者中,增加β受体阻滞剂剂量与糖尿病患者的预后获益大于非糖尿病患者。
研究设计与样本
- 前瞻性队列研究,纳入2006年至2014年间招募的1797例慢性心力衰竭患者,平均随访4年。
主要发现
- 糖尿病患者处方的β受体阻滞剂和ACEI剂量大于非糖尿病患者。
- β受体阻滞剂剂量增加与死亡率降低相关:糖尿病患者每mg/日降低8.9%(95%CI 5-12.6),非糖尿病患者每mg/日降低3.5%(95%CI 0.7-6.3),交互作用P=0.027。
- ACEI剂量增加与死亡率降低相关:糖尿病患者每mg/日降低5.9%(95%CI 2.5-9.2),非糖尿病患者每mg/日降低5.1%(95%CI 2.6-7.6),交互作用P=0.76。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes increases mortality in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction. Studies have questioned the safety of β-adrenoceptor blockers (β-blockers) in some patients with diabetes and reduced left ventricular ejection fraction. We examined whether β-blockers and ACE inhibitors (ACEIs) are associated with differential effects on mortality in CHF patients with and without diabetes. RESEARCH DESIGN AND METHODS: We conducted a prospective cohort study of 1,797 patients with CHF recruited between 2006 and 2014, with mean follow-up of 4 years. β-Blocker dose was expressed as the equivalent dose of bisoprolol (mg/day) and ACEI dose as the equivalent dose of ramipril (mg/day). Cox regression analysis was used to examine the interaction between diabetes and drug dose on all-cause mortality. RESULTS: Patients with diabetes were prescribed larger doses of β-blockers and ACEIs than were patients without diabetes. Increasing β-blocker dose was associated with lower mortality in patients with diabetes (8.9% per mg/day; 95% CI 5-12.6) and without diabetes (3.5% per mg/day; 95% CI 0.7-6.3), although the effect was larger in people with diabetes (interaction P = 0.027). Increasing ACEI dose was associated with lower mortality in patients with diabetes (5.9% per mg/day; 95% CI 2.5-9.2) and without diabetes (5.1% per mg/day; 95% CI 2.6-7.6), with similar effect size in these groups (interaction P = 0.76). CONCLUSIONS: Increasing β-blocker dose is associated with a greater prognostic advantage in CHF patients with diabetes than in CHF patients without diabetes.
引用
- Witte KK, Drozd M, Walker AMN, et al. Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes. Diabetes Care. 2017. PMID: 28982651. doi:10.2337/dc17-1406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。